Cargando…

Progression‐free survival at 3 years is a reliable surrogate for 5‐year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma

BACKGROUND: Despite 3‐year survival being used as a primary endpoint in some randomized controlled trials (RCTs), limited evidence supports the use of intermediate endpoints to evaluate the effect of new therapies in esophageal squamous cell cancer (ESCC). This study aimed to systematically evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yu‐Xian, Zheng, Yu‐Zhen, Gao, Tian‐Tian, Liu, Shi‐Liang, Xi, Mian, Liu, Meng‐Zhong, Wang, Jun‐Ye, Qi, Shu‐Nan, Yang, Yong, Zhao, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582670/ https://www.ncbi.nlm.nih.gov/pubmed/35434962 http://dx.doi.org/10.1002/cam4.4751

Ejemplares similares

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
por: Han, Weiming, et al.
Publicado: (2022)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
por: Jiménez‐Ubieto, Ana, et al.
Publicado: (2017)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Elevated Maspin Expression Is Associated with Better Overall Survival in Esophageal Squamous Cell Carcinoma (ESCC)
por: Wang, Yang, et al.
Publicado: (2013)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma
por: Huang, Guo-Wei, et al.
Publicado: (2018)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
por: Belin, Lisa, et al.
Publicado: (2020)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

A seven-lncRNA signature predicts overall survival in esophageal squamous cell carcinoma
por: Mao, Yu, et al.
Publicado: (2018)

Postoperative serum squamous cell carcinoma antigen and carcinoembryonic antigen predict overall survival in surgical patients with esophageal squamous cell carcinoma
por: Huang, Yi, et al.
Publicado: (2023)

A Novel Ferroptosis-Related Biomarker Signature to Predict Overall Survival of Esophageal Squamous Cell Carcinoma
por: Song, Jiahang, et al.
Publicado: (2021)

Development and validation of a nomogram to predict overall survival of T1 esophageal squamous cell carcinoma patients with lymph node metastasis
por: Yu, Jia, et al.
Publicado: (2021)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

The Impact of Preoperative Nutritional Status on the Survival of Patients With Esophageal Squamous Cell Carcinoma
por: Chen, Shao-bin, et al.
Publicado: (2021)

Is there hope in improving 5-year overall survival?—review of 5-year overall survival data from KEYNOTE-001
por: Akingbemi, Wisdom, et al.
Publicado: (2020)

Combined heavy smoking and drinking predicts overall but not disease-free survival after curative resection of locoregional esophageal squamous cell carcinoma
por: Sun, Peng, et al.
Publicado: (2016)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yin, et al.
Publicado: (2022)

Predictive Model for Overall Survival and Cancer-Specific Survival in Patients with Esophageal Adenocarcinoma
por: Huang, He, et al.
Publicado: (2021)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Nomogram forecasting 3‐, 5‐, and 8‐year overall survival and cancer‐specific survival of gingival squamous cell carcinoma
por: Yan, Lei, et al.
Publicado: (2020)

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis
por: Yang, Yin, et al.
Publicado: (2022)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer
por: Gyawali, Bishal, et al.
Publicado: (2021)

The Impact of Lymphopenia and Dosimetric Parameters on Overall Survival of Esophageal Cancer Patients Treated with Definitive Radiotherapy
por: Liu, Ming, et al.
Publicado: (2021)

A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
por: Zhang, Shu-Wen, et al.
Publicado: (2022)

Trends in conditional overall survival of esophageal cancer: a population-based study
por: Deng, Wei, et al.
Publicado: (2021)

The impact of the nodal status on the overall survival of non-surgical patients with esophageal squamous cell carcinoma
por: Zhao, Zongxing, et al.
Publicado: (2019)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
por: Duan, Jingjing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7b5q78n3tbg8pghvg9up8vf8c4